Trial · NCT03175367
Adverse events940
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
381 to 400 of 940
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Upper respiratory tract infection | Infections and infestations | Group A: Placebo SC QW (DBTP) | 0 | 39 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 0 | 39 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Group A: Evinacumab 300 mg SC QW (DBTP) | 2 | 42 | 2 |
| other | Upper respiratory tract infection | Infections and infestations | Group A: Evinacumab 450 mg SC QW (DBTP) | 2 | 40 | 2 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Placebo IV Q4W (DBTP) | 0 | 33 | 0 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP) | 1 | 36 | 1 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP) | 1 | 37 | 1 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Placebo IV Q4W (OLTP) | 2 | 31 | 2 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Evinacumab 5 mg/kg IV Q4W (OLTP) | 3 | 32 | 4 |
| other | Upper respiratory tract infection | Infections and infestations | Group B: Evinacumab 15 mg/kg IV Q4W (OLTP) | 3 | 33 | 3 |
| other | Urinary tract infection | Infections and infestations | Group A: Placebo SC QW (DBTP) | 4 | 39 | 7 |
| other | Urinary tract infection | Infections and infestations | Group A: Evinacumab 300 mg SC Q2W (DBTP) | 5 | 39 | 6 |
| other | Urinary tract infection | Infections and infestations | Group A: Evinacumab 300 mg SC QW (DBTP) | 5 | 42 | 6 |
| other | Urinary tract infection | Infections and infestations | Group A: Evinacumab 450 mg SC QW (DBTP) | 4 | 40 | 6 |
| other | Urinary tract infection | Infections and infestations | Group B: Placebo IV Q4W (DBTP) | 0 | 33 | 0 |
| other | Urinary tract infection | Infections and infestations | Group B: Evinacumab 5 mg/kg IV Q4W (DBTP) | 2 | 36 | 3 |
| other | Urinary tract infection | Infections and infestations | Group B: Evinacumab 15 mg/kg IV Q4W (DBTP) | 0 | 37 | 0 |
| other | Urinary tract infection | Infections and infestations | Group B: Placebo IV Q4W (OLTP) | 2 | 31 | 2 |
| other | Urinary tract infection | Infections and infestations | Group B: Evinacumab 5 mg/kg IV Q4W (OLTP) | 6 | 32 | 8 |
| other | Urinary tract infection | Infections and infestations | Group B: Evinacumab 15 mg/kg IV Q4W (OLTP) | 3 | 33 | 7 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03175367/events?page=20